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YO-PRO-1 dye uptakeThe P2X7 receptor (P2X7R) plays an important role in diverse conditions associated with tissue damage
and inflammation, meaning that the human P2X7R (hP2X7R) is an attractive therapeutic target. The crys-
tal structures of the zebrafish P2X4R in the closed and ATP-bound open states provide an unprecedented
opportunity for structure-guided identification of new ligands. The present study performed virtual
screening of 100,000 structurally diverse compounds against the ATP-binding pocket in the hP2X7R.
This identified three compounds (C23, C40 and C60) out of 73 top-ranked compounds by testing against
hP2X7R-mediated Ca2+ responses. These compounds were further characterised using Ca2+ imaging,
patch-clamp current recording, YO-PRO-1 uptake and propidium iodide cell death assays. All three com-
pounds inhibited BzATP-induced Ca2+ responses concentration-dependently with IC50s of 5.1 ± 0.3 lM,
4.8 ± 0.8 lM and 3.2 ± 0.2 lM, respectively. C23 and C40 inhibited BzATP-induced currents in a reversible
and concentration-dependent manner, with IC50s of 0.35 ± 0.3 lM and 1.2 ± 0.1 lM, respectively, but sur-
prisingly C60 did not affect BzATP-induced currents up to 100 lM. They suppressed BzATP-induced YO-
PRO-1 uptake with IC50s of 1.8 ± 0.9 lM, 1.0 ± 0.1 lM and 0.8 ± 0.2 lM, respectively. Furthermore, these
three compounds strongly protected against ATP-induced cell death. Among them, C40 and C60 exhibited
strong specificity towards the hP2X7R over the hP2X4R and rP2X3R. In conclusion, our study reports the
identification of three novel hP2X7R antagonists with micromolar potency for the first time using a
structure-based approach, including the first P2X7R antagonist with preferential inhibition of large pore
formation.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
P2X receptors are a family of trimeric protein complexes that
function as ATP-gated calcium-permeable, nonselective cationic
channels [32]. The P2X7 receptor (P2X7R), the last identified mem-
ber of the P2X receptor family, acts as an ion channel during brief
stimulation. However, prolonged receptor activation can induce
the formation of large pores which allow the passage of molecules
of up to 900 Da in size which ultimately results in cell death.
Because of this, the P2X7R is known as a cytolytic receptor [42].
The P2X7R is found in almost all tissues of the body, beingexpressed in particular in cells of haematopoietic origin [22]. It
plays an important role in a diversity of conditions associated with
tissue damage or inflammation including chronic pain, rheumatoid
arthritis and age-related macular degeneration, making the P2X7R
an attractive therapeutic target [33,38,1]. Huge drug discovery
efforts over the past few years have led to the discovery of numer-
ous P2X7R antagonists [17,41,27]. Whilst clinical trials of the first
two P2X7R antagonists against rheumatoid arthritis showed disap-
pointing outcomes [26,39], a more recent clinical trial shows pro-
mise in the therapeutic use of a P2X7R antagonist (AZD9056) in the
treatment of moderate-to-severe Crohn’s disease [10].
In order to exploit the full potential of P2X7R antagonists as
therapeutics, further efforts are inevitably required to develop
more cost-effective and efficient drug discovery approaches. These
will help to expand the structural diversity of P2X7R antagonists as
well as to develop tools which will help us better understand the
role of the P2X7R in disease mechanisms, particularly its large pore
formation [37,43,14]. None of the known antagonists can
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forming functionalities of the P2X7R. Furthermore, all the currently
available P2X7R antagonists have been discovered by high-
throughput screening which involves the random testing of large
compound libraries against the receptor; a process that is often
time-consuming, costly and inefficient. A relatively recent break-
through in the study of P2X receptors is the determination of the
atomic structures of the zebrafish P2X4R (zfP2X4R) in both the
apo, closed, and ATP-bound, open, states [18]. Homology models
of the P2X7R have been useful in providing structural insights into
the effects of disease-associated mutations on P2X7R function
[7,35,2,24] and the striking species difference of P2X7R antagonists
[6]. The key residues coordinating ATP binding identified in the
ATP-bound zfP2X4R structure are almost completely conserved
through the mammalian P2X receptors [4] but not all the residues
participating in the formation of the ATP-binding pocket are iden-
tical [24]. The ATP binding pocket in itself is unconventional, not
consisting of a well-known ATP binding motif such as the Walker
motif. As such, this region is a favourable target for therapeutic
compounds due to its reduced likelihood of interactions with other
vital ATP-binding proteins. Such structural features offer a feasible
opportunity permitting the structure-based identification of small
molecules which bind to this ATP-binding pocket with receptor-
subtype specificity. In the present study, we used a sphere 10 Å
in diameter encompassing the ATP-binding pocket in the hP2X7R
homology model in the virtual screening of a structurally diverse
compound database. In combination with functional assays, we
have identified three structurally novel hP2X7R antagonists,
including the first hP2X7R antagonist which displays selective
inhibition of the large pore formation without having an effect
on the ion channel function.2. Materials and methods
2.1. Chemicals
General chemicals used in the study, ATP, 2,3-O-(4-
benzoylbenzoyl)-ATP (BzATP), trinitrophenyl-ATP (TNP-ATP), bril-
liant blue G (BBG), YO-PRO-1 iodide, propidium iodide (PI) and
G418 were purchased from Sigma (Dorset, UK). AZ11645373 and
5-BDBD were from Tocris Bioscience (Bristol, UK). All 73 com-
pounds tested in the study (C1-C73) were sourced from Enamine
(Ukraine) with a purity of P93% determined by high performance
liquid chromatography analysis.
2.2. Homology modelling
Structural models of the human and rat P2X7R were produced
based on the atomic structures of the zfP2X4R in the apo, closed
state and ATP-bound open state (Protein Data Bank code 4DW0
and 4DW1, respectively) using Modeller version 9.12 [11], as
described in our previous studies [21,6]. In brief, one hundred ver-
sions of the P2X7R were generated for each model and the five
with the lowest energy were analysed using MolProbity [8]. Those
with the greatest percentage of residues in allowed regions of the
Ramachandran plot were selected for use in further investigations.
The non-conserved loop region between the b2 and b3 strands was
modelled de novo using the ModLoop server [13].
2.3. Virtual screening
Virtual screening was carried out using eHiTS version 12 [45].
The ATP-binding pocket file used in the screening was produced
in SPROUT [16] and consisted of a sphere 10 Å in diameter centred
on the bound ATP molecule. The ZINC12 database, containingapproximately 100,000 structurally diverse compounds [20], were
docked to this ATP-binding pocket. 500 of the best eHiTS scoring
compounds were further scored using SPROUT. 42 of the 50 com-
pounds (C1–C42) ranked with the highest predicted energy bind-
ing scores were commercially available and were tested in the
initial functional assay. Further screening of the ZINC12 database
was performed based on structural similarity using the ZINC12
website search function in order to carry out ‘structure-activity
relationships by catalogue’ against the common shapes and func-
tional groups of the two hits (C23 and C40). The top 31 compounds
(C43–C73) with >80% structural similarity were tested in func-
tional assays. PyMOL [9] was used for the visual inspection of
ligand-receptor interactions and later graphical representations.
2.4. Cell culture
Human embryonic kidney (HEK) 293 cells stably expressing C-
terminally EE-tagged human or rat P2X7R [42,34], human P2X4R
[15] and rat P2X3R [28] were generated in previous studies. A
stable HEK293 cell line expressing C-terminally His-tagged human
P2X7R was generated in this study and there was no difference in
the experimental results using EE-tagged and His-tagged human
P2X7R. These cells were maintained in Dulbecco’s Modified Eagle
Medium (Life Technologies) supplemented with 10% foetal bovine
serum and 200 ng/ml G418 in a tissue culture incubator at 37C
and 5% CO2 under humidified conditions. Cells were cultured in
T25 flasks and split (every 3–4 days) once confluent.
2.5. Calcium measurements
FlexStation II and III (Molecular Devices) were used to measure
intracellular Ca2+ concentrations ([Ca2+]i). Human or rat P2X7R-
expressing HEK293 cells were plated in poly-D-lysine-coated 96-
well plates (Molecular Devices) with 50,000 cells per well 24 h
prior to use. Cells were rinsed with standard buffer solution
(SBS) containing: 134 mM NaCl, 5 mM KCl, 1.2 mM MgCl2 and
1.5 mM CaCl2, 8 mM glucose, 2.4 mM HEPES, pH 7.4. After 100 ll
of loading buffer consisting of SBS containing 1 lM Fura-2/AM (Life
Technologies) and 0.01% (v:v) pluronic acid (ThermoFisher) was
added to each well, the plate was incubated at 37 C for 45 min.
Cells were rinsed once with SBS, after which 160 ll of SBS contain-
ing either 0.01–0.02% dimethyl sulphoxide (DMSO) used to prepare
compound stock solutions or test compound were added to each
well. The plate was incubated at 37 C for 30 min. Cells were
excited at 340 nm and 380 nm alternatively and the emission at
510 nm recorded using a FlexStation. The ratio of fluorescence
intensity (F340/F380) was used to indicate the [Ca2+]i. The basal
[Ca2+]i was recorded for 60 s prior to the exposure to agonist and
recording was continued for a further 120 s. BzATP at 300 lM
was used to evoke maximal activation of human and rat P2X7R
(e.g. [3]), and ATP at 100 lM at the hP2X4R and rP2X3R [28,15].
The maximal changes in F340/F380 (DF340/380) were used for
quantitative analysis.
2.6. Patch-clamp recording
Membrane ionic currents were measured using patch-clamp
recording in the whole-cell configuration at room temperature
using an Axopatch 200B amplifier and analysed with pClamp
10.3 software (Axon Instruments) as described in our previous
study [2]. In brief, HEK293 cells expressing the hP2X7R were
seeded onto 10-mm glass cover slips prior to use. The cover slip
was placed in a recording chamber connected to a solution
exchange system driven by a gravity feed at a rate of 5 ml min1.
Patch microelectrodes with a resistance of approximately
1–5 MX were produced using borosilicate glass capillaries (World
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80 mV. Agonists and antagonists were applied using a rapid solu-
tion changer (RSC-160, Biologic Science Instruments). The standard
extracellular solution contained: 147 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 2 mM CaCl2, 10 mM HEPES, and 13 mM glucose. The intra-
cellular solution contained: 145 mM NaCl, 10 mM EDTA and
10 mM HEPES. Divalent cations are known to strongly inhibit the
P2X7R [42] and thus in a majority of experiments agonist-
induced currents were recorded in low divalent extracellular solu-
tion containing: 147 mM NaCl, 2 mM KCl, 0.3 mM CaCl2, 10 mM
HEPES and 22 mM glucose. All solutions were adjusted to pH 7.3
with 5 M NaOH. The currents were evoked by 4 s application of
300 lM BzATP with an interval of 2–4 min and the peak currents
were used for quantitative analysis as described in our previous
studies [3].
2.7. YO-PRO-1 uptake assay
YO-PRO-1 uptake was recorded mainly using FlexStation as
described in a previous study [5]. HEK293 cells expressing the
hP2X7R were seeded in poly-D-lysine coated 96-well plates as
described above for Ca2+ measurements. The assay buffer com-
prised: 147 mM NaCl, 2 mM KCl, 0.3 mM CaCl2, 10 mM HEPES,
and 22 mM glucose, pH 7.3. Cells were washed with assay buffer
and incubated at 37 C for 20 min with 80 ll of assay buffer con-
taining 1 lM YO-PRO-1 with either DMSO or the test compound.
Cells were excited at 485 nm and the emission recorded at
530 nm. Recordings lasted 120 s and BzATP was added at 20 s with
a final concentration of 300 lMwhich is known to induce maximal
P2X7 receptor-dependent dye uptake [25,3]. The maximal changes
in F530 were used for quantitative analysis. Single cell imaging was
also used to examine the effect of C60 on ATP-induced hP2X7R-
dependent dye uptake. Cells were plated in 24-well plates with
20,000 cells per well 24 h prior to use. 1 mM ATP alone or with
5 lM C60 and 10 lM C10 as well as YO-PRO-1 at a final concentra-
tion of 1 lM were added into the cell culture media and incubated
at 37 C for 30 min. Cells were imaged using an EVOS FL cell imag-
ing system (Life Technologies). For each well, YO-PRO-1 stained
cells were counted in one randomly selected field and presented
as the percentage of the total number of cells identified by DAPI
staining in the same field. Cell counting was carried out using
ImageJ.
2.8. PI staining cell death assay
PI staining was used to assess cell death as described in our pre-
vious study [29] in cells treated with ATP, a condition that is sim-
ilar to P2X7 receptor-mediated cell death under pathological
conditions such as tissue damage and inflammation. Cells were
plated in six well-plates with 40,000 cells per well 24 h prior to
use. ATP at 3 mM alone or together with the test compounds at
the indicated concentrations were added to the culture media
and cells were incubated at 37 C and 5% CO2 for 6 h. PI was added
with a final concentration of 5 lg/ml and cells were incubated for a
further 30 min. Cells were counterstained with DAPI. Images were
captured using an EVOS FL cell imaging system (Life Technologies).
For each well, PI-stained cells were counted in one randomly
selected field and presented as the percentage of the total number
of cells identified by DAPI staining in the same field. Cell counting
was carried out using ImageJ.
2.9. Data presentation and analysis
All results, where appropriate, are presented as mean ± stan-
dard error of the mean (SEM). The antagonist concentrations evok-
ing half inhibition (IC50) were derived using Origin to fit the datafrom each independent experiment (Ca2+ response and YO-PRO-1
uptake) or cells (current) to the Hill equation: I = 100/(1 + ([B]/
IC50)n), where I is the BzATP-induced responses (Ca2+ response,
current or YO-PRO-1 uptake) following exposure to identified con-
centrations of antagonist ([B]) and expressed as the percentage of
the control responses and n is Hill coefficient. The solid line shown
in the figures represent the fitting of mean data. Statistical analysis
was carried out using Origin. Student’s t-test was used for two
groups and one-way analysis of variance test and Tukey’s post
hoc test for more than two groups, and the difference was consid-
ered to be significant at p < 0.05.
3. Results
3.1. Identification of novel hP2X7R antagonists by structure-based
virtual screening
Comparison of the ATP-bound zfP2X4R structure and the
hP2X7R homology model reveals 62% amino acid sequence identity
between these receptors within the ATP-binding pocket in a 10 Å
sphere centred on the bound ATP molecule (Fig. 1A–B). The essen-
tial nature of the ATP binding pocket and its non-traditional fold in
the hP2X7R made it a suitable target to perform virtual screening
of the ZINC12 database, which contains approximately 100,000
structurally diverse compounds [20]. Each compound was docked
individually into the ATP-binding pocket using eHiTS (e.g.,
Fig. 1C) with a corresponding predicted energy binding score being
calculated. For the 50 compounds with the highest scores, 42 were
commercially available and had predicted energy binding scores
ranging from 4 to 10.5 kcal/mol. These values are comparable
to those predicted for known hP2X7R antagonists including
AZ11645373 (10.8 kcal/mol), SB203580 (8.75 kcal/mol) and
KN-62 (5.2 kcal/mol) as reported in our recent study [6]. To ini-
tially test the top 42 compounds we applied the compounds at
10 lM to determine their effects on Ca2+ responses in HEK293 cells
expressing hP2X7R induced by 300 lM BzATP, a structural ana-
logue of ATP which is more potent than ATP at the P2X7R and is
predicted to bind to the ATP-binding site (data not shown). None
of the compounds showed detectable agonist activity. Two com-
pounds, ZINC67825876 (C23 from here onward) and
ZINC58368839 (C40), inhibited BzATP-induced Ca2+ responses by
73.2 ± 2% and 84.3 ± 7% respectively, whilst all other compounds
had no or modest effect, as illustrated by ZINC19868610 (C10)
(Fig. 1D and F). The inhibition by C23 and C40 was similar to that
by BBG (71.5 ± 5%) and AZ11645373 (81.9 ± 5%) (Fig. 1D and F).
These 42 compounds were also tested against BzATP-induced
Ca2+ responses in HEK293 cells expressing the rP2X7R (Fig. 1E
and G). BBG was used as a positive control and strongly inhibited
BzATP-induced Ca2+ responses, whereas AZ11645373 was far less
effective (Fig. 1F). None of the compounds caused significant inhi-
bition of the rP2X7R, including C23 and C40 (Fig. 1E and F). Exam-
ination of C23 and C40 reveals noticeable similarities as well as
substantial differences in their structures (Table 1). A number of
additional compounds with a high level of structural similarity
(P80%) were identified from the ZINC12 database using the
ZINC12 website search function. The top 31 compounds from this
new search were tested at 10 lM against the human and rat
P2X7R using FlexStation measurements of BzATP-induced Ca2+
responses. ZINC09315614 (C60) almost completely ablated
BzATP-induced Ca2+ responses in hP2X7R-expressing cells
(91.2 ± 4%), and also significantly but less effectively attenuated
BzATP-induced Ca2+ responses in rP2X7R-expressing cells
(66.2 ± 22%) (Fig. 1G). These results show that the application of
a structure-based approach by combining structural homology
modelling, virtual screening and functional assays enabled the
identification of C23, C40 and C60, which represent 3 out of a total
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Fig. 1. Three compounds identified from virtual screening of the ZINC12 database that inhibit the hP2X7R. A. The trimeric hP2X7R homology model in the closed state, with
an ATP molecule docked to one of the three inter-subunit ATP-binding pockets. The 10 Å sphere ATP-binding pocket centred on the bound ATP molecule is highlighted in
green. B. The predicted ATP binding conformation within the ATP-binding pocket in the hP2X7R. C. Docking of compound C23 (green) from the ZINC12 compound library in
the ATP-binding pocket in the hP2X7R and ATP (silver) shown for comparison. D. The predicted binding BzATP conformation within the ATP-binding pocket in the hP2X7R. E–
F. Representative Flex-Station recordings of Ca2+ responses induced by 300 lM BzATP in HEK293 cells expressing the hP2X7R (E) and rP2X7R (F), with the control responses
shown in black and the responses in cells treated with compound C10, C23 or C40 at 10 lM in red. 200 nM AZ11645373 and 10 lM BBG were used as the positive control
inhibiting the human and rat P2X7R respectively. G. Summary of the effects of 42 compounds on BzATP-induced Ca2+ responses mediated by the hP2X7R shown in black and
the rP2X7R in grey. Results were from 8 to 12 wells of cells from 3 independent experiments. H. Summary of the effects of 31 compounds with structural similarity to C23 and
C40 on BzATP-induced Ca2+ responses mediated by the hP2X7R shown in black and the rP2X7R in grey. Results were from 8 to 12 wells of cells from 3 to 5 independent
experiments. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Table 1
Summary of chemical and pharmacological properties of novel hP2X7R antagonists.
Compound ID ZINC12 database ID Chemical structure IC50 (lM)
(Ca2+ response)
IC50 (lM)
(current)
IC50 (lM)
(dye uptake)
C23 ZINC 67825876 5.1 ± 0.3 0.35 ± 0.3 1.8 ± 0.9
C40 ZINC 58368839 4.8 ± 0.8 1.2 ± 0.1 1.0 ± 0.1
C60 ZINC 09315614 3.2 ± 0.2 100 0.8 ± 0.2
134 E.A. Caseley et al. / Biochemical Pharmacology 116 (2016) 130–139of 73 compounds tested, and cause strong inhibition of the
hP2X7R.3.2. Further pharmacological characterisation of C23, C40 and C60
The potency of C23, C40 and C60 when inhibiting the hP2X7R
was further characterised by recording BzATP-induced Ca2+
responses and currents in HEK293 cells expressing the hP2X7R.
The FlexStation and patch-clamp recording were used respectively,
as these methods represent the most commonly used techniques
in the study of ion channel pharmacology. As illustrated in Fig. 2,
these three compounds inhibited Ca2+ responses induced by
300 lM BzATP in a concentration-dependent manner, with
complete inhibition at the highest concentrations applied
(10–30 lM). Fitting the concentration-response relationship
curves to the Hill equation yielded IC50 values of 5.1 lM ± 0.3 lM
(n = 6), 4.8 ± 0.8 lM (n = 6) and 3.2 ± 0.2 lM (n = 6) for C23, C40
and C60, respectively (Fig. 2A–C). Similarly, C23 and C40
concentration-dependently inhibited BzATP-induced currents,
with IC50 values of 0.35 ± 0.3 lM (n = 6) and 1.2 ± 0.1 lM (n = 6)
respectively (Fig. 3A–C). Current inhibition was complete and read-
ily reversed upon washing (Fig. 3A). Surprisingly, despite exhibit-
ing similar potency as C23 and C40 in inhibiting BzATP-inducedFig. 2. Concentration-dependent effects of C23, C40 and C60 on BzATP-induced Ca2+
induced by 300 lM BzATP in control cells or cells treated with C23 (A), C40 (B) and C60 (
curves with the solid lines representing the fit of the mean data to Hill equation. Each d
experiments.Ca2+ responses, C60 caused no inhibition of BzATP-induced cur-
rents even when applied at 30–100 lM (Fig. 3A and D). BzATP-
induced currents in the same current recordings were abolished
by the subsequent application of C23 (Fig. 3A).
As introduced above, prolonged P2X7R activation can induce
large pore formation. This can be visualised under physiological
conditions by monitoring the uptake of fluorescent dyes with large
molecular weights such as YO-PRO-1 (375 Da) [44]. C23, C40 and
C60 were further investigated to see if they inhibited P2X7R-
dependent large pore formation using FlexStation to measure
YO-PRO-1 uptake in hP2X7R-expressing HEK293 cells. C23, C40
and C60 concentration-dependently inhibited YO-PRO-1 uptake
induced by 300 lM BzATP, with IC50 values of 1.8 ± 0.9 lM
(n = 12), 1.0 ± 0.1 lM (n = 12) and 0.8 ± 0.2 lM (n = 16), respec-
tively (Fig. 4A–C). We also used single cell imaging to examine
the effect of C60 on ATP-induced hP2X7R-dependent dye uptake.
The percentage of YO-PRO-1 positive cells was increased by >4
times upon treatment with 1 mM ATP for 30 min (14.7 ± 4.0%
and 63.0 ± 11.7% in control cells and ATP-treated cells, n = 3,
p < 0.01). The percentage of YO-PRO-1 positive cells in ATP-
treated cells was significantly reduced by treatment with 5 lM
C60 (33.8 ± 5.6%, n = 3, p < 0.001) but not affected by treatment
with 10 lM C10 (69.2 ± 3.2%, n = 3; p > 0.05). These results provideresponses in hP2X7R-expressing HEK293 cells. Top, representative Ca2+ responses
C) at the indicated concentrations. Bottom, concentration-Ca2+ response relationship
ata point represents the mean from 8 to 12 wells of cells from 3 to 5 independent
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dependent large pore formation.
Taken together, these results provide clear evidence to show
that C23 and C40 inhibit both hP2X7R ion channel activation and
large pore formation but C60 preferentially targets large pore for-
mation without effect on the ion channel function.
3.3. Effects of C23, C40 and C60 on other P2XRs
C23, C40 and C60 were examined next for their specificity by
determining their effects on the other members of the P2X receptorfamily, particularly the hP2X4R. The P2X4R has the highest level of
sequence identity with the P2X7R over the whole receptor and also
at the ATP-binding pocket used in virtual screening and, further-
more, the two receptors co-exist in many cell types. C23 applied
at 10 lM strongly reduced 100 lM ATP-induced Ca2+ responses
in hP2X4R-expressing HEK293 cells in a manner comparable to
the P2X4R antagonist 5-BDBD (Fig. 5A and B). However, both C40
and C60 also applied at 10 lM resulted in no significant effect
(Fig. 5A and B). The three compounds were further tested in
rP2X3R-expressing HEK293 cells, in which 100 lM ATP induced
Ca2+ responses with transient kinetics (Fig. 5A) due to the strong
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effective at 10 lM in suppressing rP2X3R-mediated ATP-induced
Ca2+ responses in a manner similar to the P2X3R antagonist TNP-
ATP (Fig. 3A and B). Both C40 and C60 caused smaller but statisti-
cally insignificant inhibition (Fig. 5A and B). Therefore, whilst C23
is largely indiscriminate, both C40 and C60 exhibit much greater
specificity towards the hP2X7R.
3.4. Inhibition of P2X7R-mediated cell death
The P2X7R is a well-known cytolytic receptor which plays a
critical role in mediating ATP-induced cell death in vivo under
pathological conditions as well as under in vitro experimental con-
ditions, a unique functional role which distinguishes the P2X7R
from all the other P2X receptors [22]. As such, inhibition of the
P2X7R offers protection against ATP-mediated cell death in a num-
ber of cells expressing the P2X7R [12,30,36]. Therefore, C23, C40
and C60 compounds were finally tested for their effectiveness in
preventing ATP-induced cell death in hP2X7R-expressing HEK293
cells to provide further supporting evidence for their action on
the hP2X7R. Exposure of cells to 3 mM ATP for 6 h caused cell
death by 74 ± 7% (n = 12) as determined by PI staining assays
(Fig. 6A and B). Pre-treatment with C23 at 3 and 10 lM, C40 at 3
and 10 lM or C60 at 10 and 30 lM strongly reduced ATP-induced cell death by approximately or >50% (Fig. 6A and B). These
results provide further evidence to support the notion that com-
pounds identified in this study inhibit the hP2X7R.
4. Discussion
Studies over the past decade have revealed a crucial role for the
P2X7R in a range of debilitating disease conditions [23]. Emerging
evidence supports the hP2X7R as a druggable target [10]. In order
to exploit the full potential of hP2X7R antagonists as therapeutics,
more efforts are required to increase the structural diversity of
hP2X7R antagonists as well as to better understand the underlying
disease mechanisms. All currently known P2X7R antagonists have
been identified through the random functional screening of large
compound libraries, which can be time-consuming, costly and
inefficient. Using virtual screening of a large set of compounds
against the hP2X7R ATP-binding pocket followed by functional
assays, the present study identified two hits (C23 and C40)
(Fig. 1D and F). A further 31 compounds were generated based
on structural similarities to C23 and C40 which identified a third
compound, C60 (Fig. 1G). Detailed functional characterisations,
by determining their effects on hP2X7R-mediated Ca2+ responses,
currents and YO-PRO-1 uptake, consistently indicate micromolar
potency at the hP2X7R, albeit with some variations that are likely
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Fig. 6. Effects of C23, C40 and C60 on ATP-induced cell death in hP2X7-expressing HEK293 cells. A. Representative fluorescent images showing all cells identified by DAPI
staining and PI-stained dead cells under the conditions indicated. Cells were treated with 3 mM ATP alone or together with compounds at the indicated concentrations for 6 h,
and untreated cells were used as a control (CTL). Scale bar is 100 lm. B. Summary of percentage of cell death under the indicated conditions. Results are presented as the
mean from 12 independent experiments. **, p < 0.01 compared to control. ++, p < 0.05 compared to cells treated with alone.
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three compounds effectively protected against ATP-induced cell
death (Fig. 6), providing further evidence to support that they
antagonise the hP2X7R. Subtype specificity is of great importance
when using antagonists in the study of the role of the hP2X7R in
ATP-induced physiological functions and diseases as well as for
the development of therapeutic compounds. Of these three com-
pounds, C40 and C60 exhibited significant specificity towards the
hP2X7R over the other P2X receptors examined (Fig. 5), including
the hP2X4R which shares the highest level of sequence identity
with the hP2X7R. Thus, it is unlikely but remains to be confirmed
that C40 and C60 cause potent inhibition at the other P2X recep-
tors with less structural similarity to the hP2X7R. Evidently,
structure-activity relationship studies are required for structural
optimisation of these compounds in order to further improve their
potency and specificity. Nonetheless, the present study is the first
to identify structurally novel P2X7R antagonists using a structure-
based approach, which can be more time-saving and cost-effective
than the conventional screening approach.
It has been well-documented that prolonged or repeated activa-
tion of the P2X7R induces large pore formation, but it still remains
a subject of debate if this is through P2X7R itself or via the activa-
tion of a distinctive protein which forms the large pore [32,44,21].
Regardless of the underlying mechanisms, recent studies show that
P2X7R-dependent large pore functionality is of high relevance to
the pathogenesis of diseases such as chronic pain [37], osteoporo-
sis [43], and aged-related macular degeneration responsible for the
loss of vision in elderly people [14]. Emerging evidence supports
that blocking this pore is a valuable therapeutic intervention
[14]. None of the currently available P2X7R antagonists effectively
discriminate between the ion channel and large pore functions. In
this regard, C60 is of interest as it is the first reported P2X7R antag-
onist that selectively prevents large pore formation (Fig. 4) without
affecting the ion channel function (Fig. 3). C60 will be useful as a
pharmacological tool to better understand large pore formation
and its role in P2X7R-mediated physiological functions and dis-eases. It may also act as a potential lead compound for
development of therapeutics targeting this pivotal pore-forming
function.
C23, C40 and C60 all contain an N-methyl amide group in their
structure, with a prominent NO2 group at one end and a bulky ring
structure at the opposite end (Table 1), thus suggesting that they
represent a class of new hP2X7R antagonists with a structurally
conserved pharmacophore. Preliminary studies show that replace-
ment of the NO2 group in C40 with NH2 retains activity, whereas
substitution with CH3 reduces inhibition of hP2X7R-mediated
Ca2+ responses (data not shown). This suggests that nitrogen is a
vital component of the compound structure which is possibly
required for hydrogen bonding with residues such as Gln143 in
the ATP-binding pocket (Fig. 7). A compound containing a benzene
ring structure in replacement of the bulky ring structure in C23 and
C40 is ineffective in inhibiting hP2X7R-mediated Ca2+ responses
(data not shown), implying that the bulky ring structure is pivotal
in interacting with the hP2X7R, particularly Tyr288. Furthermore,
assessment of the compound structures predicts the central com-
mon moiety is a relatively flexible linker, allowing antagonists to
adopt a bent configuration to facilitate interactions with the recep-
tor (Fig. 7). Finally, all three compounds identified in this study
preferentially inhibit the hP2X7R over the rP2X7R (Fig. 1D–G).
Such striking species specificity has been repeatedly reported for
known hP2X7R antagonists such as KN62 [19], AZ11645373 [40]
and SB203580 [31]. Examination of ligand-receptor interactions
has led us to hypothesise that the species specificity of C23, C40
and C60 arises from structural differences in the ATP-binding
pocket such as Tyr288. This residue in the hP2X7R flips further into
the ATP-binding pocket and its orientation is expected to facilitate,
whereas Phe288 in the rP2X7R is positioned in a way that is pre-
dicted to disfavour interactions with the antagonists, specifically
the bulky ring structure discussed above (Fig. 7). Further site-
directed mutagenesis studies will inform the importance of these
parts in the receptor including Gln143 and Tyr288 in determining
antagonist binding.
C23 C40 C60 
Fig. 7. Proposed structural basis for ligand-receptor interactions and species difference for C23, C40 and C60. The three hit compounds (from left to right: C23, C40 and C60)
are docked to the ATP-binding pocket in the structure homology models of hP2X7R and rP2X7R. Assessments of the ligand-receptor interactions predict that Tyr288 and
Gln143 in the hP2X7R participate in interactions with the bulky ring structure and hydrogen bonding with the NO2 group in the compounds, respectively. Whilst Tyr288 in
the hP2X7R flips further into the ATP-binding pocket to facilitate binding, Phe288 in the rP2X7R is positioned in a way that is predicted to disfavour interactions with these
antagonists.
138 E.A. Caseley et al. / Biochemical Pharmacology 116 (2016) 130–139In summary, the present study identifies for the first time struc-
turally novel hP2X7R antagonists using a structure-based approach
combining virtual screening and functional testing. It reports the
first P2X7R antagonist with preferential inhibition of the large pore
formation without effect on the ion channel function.
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